BackAkums Drugs & Pharmaceuticals Overview

Akums Drugs & Pharmaceuticals Receivables

Track Akums Drugs & Pharmaceuticals's receivables ($8B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$7.97B
↑ 2.38% YoYΔ $185.17M vs prior year quarter

Peer trimmed avg / median

Loading

Akums Drugs & Pharmaceuticals Receivables History

Loading

Akums Drugs & Pharmaceuticals vs. peers: Receivables Comparison

Loading

Akums Drugs & Pharmaceuticals Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Akums Drugs & Pharmaceuticals (AKUMS.NS) FAQ

As of the most recent data (March 2026), AKUMS.NS shows a receivables of $8B. That compares with $7.8B in the prior-year period — up 2.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, AKUMS.NS's receivables is now $8B (was $7.8B) — a 2.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Akums Drugs & Pharmaceuticals is outperforming or lagging.

Tracking AKUMS.NS's receivables over time shows whether Akums Drugs & Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $8B That compares with $7.8B in the prior-year period — up 2.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Akums Drugs & Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $8B) with ownership activity and broader fundamentals.